Aside from ketamine, the availability of psychedelics varies quite widely, and it’s often frustrating at how much more slowly legalization efforts and FDA-approval are compared to how many studies are showing efficacy for these medicines.
However, some countries have made great strides in developing avenues by which to get psychedelic therapies to patients who need them.
Specifically, Canada and Australia have both enacted some powerful regulations regarding which patients can access psychedelic medicine.
As both of these programs involve the patients’ healthcare team, we wanted to inform you all about what these programs look like and what they require of the clinicians involved.
To help us all understand these access programs better, we’ve got representatives from Canada and Australia to elucidate how their country has helped expand access to psychedelic medicines.
They’ll be discussing the following:
- What each country’s psychedelic access program looks like
- Who qualifies for treatment
- The role clinicians play in these programs
- Some of the benefits and challenges they’re facing
As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, January 25th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.
Hope to see you all on the 25th!


